RedHill Biopharma Raises $10 Million, Mulls IPO
RedHill Biopharma said it has raised $10 million in new financing from investors including Fidelity's VC biotechnology fund, Rosalind Capital and individual investors. Tel Aviv-based RedHill focuses on the acquisition and development of late clinical-stage drugs. The company also said it was considering an initial public offering on the Tel-Aviv stock exchange.
8 November 2010•3 mins read
